Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Trevi Therapeutics, Inc. (Nasdaq: TRVI) will be presenting at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024, to discuss the development of the investigational therapy Haduvio™ for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). President and CEO Jennifer Good, along with CFO Lisa Delfini, will participate in investor meetings during the virtual event.

Corporate presentation will be held on Wednesday, February 14, 2024, at 10:00 a.m. ET

NEW HAVEN, Conn., Feb. 6, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, will be presenting at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, at 10:00 a.m. ET. During this virtual event, Ms. Good along with Lisa Delfini, Chief Financial Officer, will also participate in investor meetings with attendees.  

A live webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Trevi also is evaluating Haduvio for prurigo nodularis. Haduvio is a dual ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough.

The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal relief to patients. RCC affects up to 10% of the adult population, and Haduvio's expansion into RCC has the potential to reach patients suffering from moderate to severe chronic cough. There are also no approved therapies for RCC in the US.

Parenteral nalbuphine is not scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.

Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com 

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-302053462.html

SOURCE Trevi Therapeutics, Inc.

FAQ

When is the corporate presentation for Trevi Therapeutics, Inc.?

The corporate presentation will be held on Wednesday, February 14, 2024, at 10:00 a.m. ET.

What is the ticker symbol for Trevi Therapeutics, Inc.?

The ticker symbol is TRVI.

What therapy is Trevi Therapeutics developing?

Trevi Therapeutics is developing the investigational therapy Haduvio™ for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

Who will be presenting at the Oppenheimer 34th Annual Healthcare Life Sciences Conference?

President and CEO Jennifer Good, along with CFO Lisa Delfini, will be presenting at the conference.

Where can the live webcast of the event be accessed?

The live webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com.

How long will the archived replay of the webcast be available?

An archived replay of the webcast will be available for 30 days on the Company's website following the event.